Browse News

Found 309 articles

• Valbiotis Announces Its Roadmap for 2023: a Pivotal Year in the Execution of Its Clinical, Industrial and Commercial Strategy

  1/10/2023

  Valbiotis, a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces its roadmap for 2023.

• Optinose Appoints Paul Spence as Chief Commercial Officer

  12/15/2022

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced the appointment of Paul Spence as Chief Commercial Officer.

• Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy

  11/22/2022

  Seres Therapeutics, Inc. announced that it will host an investor webcast to discuss the planned commercialization approach and market opportunity for therapeutic candidate SER-109 in recurrent C. difficile infection on Thursday, December 8, 2022, at 8:30 a.m. ET and is expected to be approximately one hour in duration.

• Study shows less snacking and reduced meal size, when using Epitomee's novel weight management aid

  11/16/2022

  Epitomee Medical, a biomedical company, develops unique ingestible devices that deploy targeted therapies along the GI tract, to treat a variety of chronic diseases and metabolic disorders.

• Aimmune Therapeutics to Present Positive Results from Phase 3 POSEIDON Study of PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] in Peanut-Allergic Children Aged 1 to 3 Years

  11/10/2022

  Aimmune Therapeutics to Present Positive Results from Phase 3 POSEIDON Study of PALFORZIA ® [Peanut ( Arachis hypogaea ) Allergen Powder-dnfp] in Peanut-Allergic Children Aged 1 to 3 Years.

• DBV Technologies Reports Third Quarter Financial Results and Business Update

  11/3/2022

  DBV Technologies, a clinical-stage biopharmaceutical company, reported financial results for the third quarter of 2022.

• Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

  11/2/2022

  Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported third quarter 2022 financial results and provided business updates.

• ChromaDex Corporation Reports Third Quarter 2022 Financial Results

  11/2/2022

  ChromaDex Corp. announced financial results for the third quarter of 2022.

• Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

  10/26/2022

  Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review.

• Allergy Partners Announces Collaboration with Aimmune Therapeutics to Provide PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] Directly to Patients

  10/13/2022

  Allergy Partners, the nation’s largest single specialty allergy practice group leading the development and delivery of high-quality health care for patients with asthma and allergic disease, today announced a strategic collaboration with Aimmune Therapeutics, Inc.

• ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment

  10/11/2022

  ChromaDex and Nestlé Health Science Announce New Niagen ® Commercial Supply Agreement and $5 Million Investment.

• Valbiotis Accelerates Its Marketing Strategy - October 07, 2022

  10/7/2022

  Valbiotis, a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, is accelerating its marketing strategy.

•  Valbiotis Provides an Update on Its Progress and Publishes Its Financial Report for the First Half of 2022

  9/15/2022

  Valbiotis announces its results for the first half of 2022 and provides an update on its developments since the beginning of the year.

• Precision Medicine Market Size, Share Report, Trends, Growth 2022-2030

  9/13/2022

  According to Vision Research Reports, the global Precision Medicine market size is expected to expand around US$ 95.5 billion by 2030 and is anticipated to grow at a CAGR of 11.9% during forecast period 2022 to 2030.

• Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection

  9/7/2022

  Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for SER-109 for the prevention of recurrent C. difficile infection (rCDI).

• Frédéric PELONG, Chief Financial Officer, Joins the Valbiotis Board of Directors

  9/6/2022

  Regulatory News: Valbiotis, a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the appointment of Frédéric PELONG to the Company’s Board of Directors.

• Biomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer

  8/30/2022

  Biomerica, Inc. announced plans to launch its InFoods® IBS test before calendar year end.

• Medical Foods Market Size to Reach US$ 33.3 Bn by 2030

  8/18/2022

  The global medical foods market was valued at US$ 18 Bn in 2022 and is anticipated to expand at a CAGR of ~6% from 2022 to 2030

• Personalized Medicine Market 2022 Industry Growth, Top Key Players, Segmentation and Forecast till 2030

  8/17/2022

  Latest Study on “Personalized Medicine Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

• FDA Infant Formula Update: August 5, 2022

  8/5/2022

  The U.S. Food and Drug Administration is providing an update on additional steps it has taken that will lead to more infant formula available in the U.S. under the agency's recent increased flexibilities.